NTRK1 and prostate carcinoma: PDGFR was seen as the most commonly amplified transcript when aspirates from prostate cancer bone metastases were evaluated for amplification of tyrosine kinase receptors, and overexpression of PDGF in prostate cancer bone metastases was confirmed by immunohistochemistry [52].